207
Participants
Start Date
December 9, 2020
Primary Completion Date
October 31, 2024
Study Completion Date
October 31, 2024
Envafolimab
PD-L1 single domain antibody for subcutaneous injection.
Ipilimumab
CTLA-4 monoclonal antibody
Columbia University, New York
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh, Pittsburgh
University of Pennsylvania, Philadelphia
Thomas Jefferson University (Sidney Kimmel Cancer Center), Philadelphia
Johns Hopkins University, Baltimore
Virginia Commonwealth University, Richmond
Duke University, Durham
Mayo Clinic, Jacksonville, Jacksonville
University of Miami, Miami
H. Lee Moffitt Cancer Center, Tampa
Vanderbilt University, Nashville
Ohio State University, Columbus
University Hospitals, Cleveland
University of Michigan, Ann Arbor
Medical College of Wisconsin, Wauwatosa
Mayo Clinic Rochester, Rochester
Northwestern University, Evanston
Washington University in St. Louis, St Louis
University of Colorado, Aurora
Huntsman Cancer Institute, Salt Lake City
University of Arizona, Tucson
Cleveland Clinic, Cleveland
University of California, Los Angeles, Los Angeles
Sarcoma Oncology Research Center, Santa Monica
Stanford University, Stanford
Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Royal Marsden, London
Tracon Pharmaceuticals Inc.
INDUSTRY